Clinical trial
A Phase 1, Double-blind, Randomized, Single Ascending Dose Study of the Safety and Tolerability of MEDI-570 in SLE
NCT01127321 is registered in ClinicalTrials.gov with MedImmune LLC as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1, Double-blind, Randomized, Single Ascending Dose Study of the Safety and Tolerability of MEDI-570 in SLE
- Lead sponsor
- MedImmune LLC
- Phase
- Phase 1
- Overall status
- Terminated
- Start date
- May 31, 2010
- Completion date
- July 31, 2012
- Enrollment
- 44 (actual)
- Sites
- 17
Conditions
As the registry lists them; a condition with its own page is linked.